Abstract 4761
Background
Cardiotoxicity is one of the effects described with anthracyclines (AC) or antiHER2 therapies. Monitoring is usually performed with an echocardiogram and the main effect is the left ventricular ejection fraction reduction. On the other hand, cardiotoxicity biomarkers, such as high-sensitivity troponin (TropHS), can be evaluated at shorter intervals and have been described as an early diagnosis indicator of myocardial injury.
Methods
Retrospective analysis of 83 breast cancer patients undergoing neoadjuvant or adjuvant chemotherapy with AC, with or without antiHER2 therapy, from January 2017 to July 2018. All patients were evaluated with cardiotoxicity biomarkers, electrocardiogram and transthoracic echocardiogram prior to treatment, and 3, 6, 9 and 12 months thereafter. After assessment of the cardiovascular risk, cardioprotective therapy has been initiated in patients with TropHS elevation. Cardiotoxicity was defined by a decline in LVEF> 10% of baseline or LVEF <50%.
Results
The median age was 49 years (26-76) and 14.5% of the patients had history of cardiovascular disease (namely arterial hypertension). Almost 29% (n = 24) were treated with association of antiHER2 therapy and the median chemotherapy treatment time was 3.8 months (1-6). About 84% (n = 70) were submitted to adjuvant radiotherapy. Eight percent had a very high (7) Cardiotoxicity Risk Score, being most of them of the group with TropHS elevation. Almost 57% (n = 47) of the patients presented TropHS elevation and we observed a major elevation at 3 months treatment, with a median of 21.25 (1.90-209.0). Approximately 5% (n = 4) of the patients had cardiotoxicity, all of them treated with combination of antiHER2 therapy, and this was more frequent in patients with TropHS elevation (p = 0.215). Among 15 patients who presented TropHs elevation and started cardioprotective therapy, only three developed cardiotoxicity. The median follow-up was 12 months (3-23).
Conclusions
Recently, the role of TropHS, as a biomarker in the early identification of cardiotoxicity, has been affirmed. The consequent use of cardioprotective agents has emerged as an effective approach in the prevention of cardiac dysfunction. For the moment, more studies are needed to validate this biomarker in clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3317 - Circulating tumor DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
Presenter: Rebecca Heist
Session: Poster Display session 1
Resources:
Abstract
3887 - First Real Life Data on Durvalumab after definitive concomitant ChemoRadiotherapy (cCRT) in unresectable Stage (St) III Non-Small Cell Lung Cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) Temporary Authorization of Use (ATU)
Presenter: Virginie Avrillon
Session: Poster Display session 1
Resources:
Abstract
682 - EGFR Inhibitor Versus Chemotherapy as Adjuvant Treatment for Locally-advanced EGFR-mutant Non-Small Cell Lung Cancer
Presenter: Peng Xie
Session: Poster Display session 1
Resources:
Abstract
2509 - Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: interim analysis of a Phase IIIb, multi-national, open-label study
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3300 - First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
Presenter: Daniel SW Tan
Session: Poster Display session 1
Resources:
Abstract
2653 - A combined analysis of two Phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3663 - Impact of plasma EGFR mutation fractions on response to first generation tyrosine-kinase inhibitor in treatment of naïve non-small cell lung cancer patients
Presenter: Xiaohong Wang
Session: Poster Display session 1
Resources:
Abstract
5921 - Definition of an afatinib trough concentration threshold in the treatment of NSCLC
Presenter: Stephane Bouchet
Session: Poster Display session 1
Resources:
Abstract
2852 - A Phase Ib Trial of Neoadjuvant Chemoradiotherapy and Durvalumab(MEDI4736) for Potentially Resectable stage III Non-Small Cell Lung Cancer (NSCLC)
Presenter: Beung chul AHN
Session: Poster Display session 1
Resources:
Abstract
3273 - Low expression of Notch1 and combined Notch1/HES1 are associated with adverse survival factor for limited stage small cell lung cancer
Presenter: Jinsoo Lee
Session: Poster Display session 1
Resources:
Abstract